AstraZeneca has unveiled a 15 billion dollar investment plan in China, underscoring renewed commercial momentum between Beijing and London as the UK prime minister visits the country. The British Swedish pharmaceutical group said the investment, running through 2030, will expand medicines manufacturing and
China is accelerating its push to become a global leader in nuclear medicine, a field that is rapidly transforming how doctors diagnose and treat cancer. With heavy state-backed investment and a fast-expanding supply of medical isotopes, China sees nuclear medicine as a strategic
China’s biotechnology sector is experiencing unprecedented growth, with startups and research institutions achieving breakthroughs that are capturing global attention. Advances in gene editing, regenerative medicine, diagnostics, and personalized therapies are transforming healthcare and attracting media coverage. This blog explores the most viral biotech
IntroductionChina’s biotech startup ecosystem is experiencing rapid growth, driven by advancements in genomics, therapeutics, medical devices, and personalized medicine. Venture capital, government funding, and corporate investment fuel innovation and expansion. Biotech startups are transforming healthcare, research, and industrial biotechnology while contributing to economic
